Table 2 Follow-up of patients enrolled in the surveillance program

BD-IPMN

36 (78.3)

5 (50.0)

31 (86.1)

MD-IPMN

7 (15.2)

3 (30.0)

4 (11.1)

MT-IPMN

3 (6.5)

2 (20.0)

1 (2.8)

Diagnosis confirmed by MRI and / or EUS

43 (93.5)

10 (100)

3 (83.3)

Diagnostic EUS-FNA

13 (28.3)

5 (50.0)

8 (22.2)

EUS-FNA during surveillance

17 (37.0

6 (60.0)

11 (30.6)

Median follow-up time (IQR) [months]

23 (27)

21 (12.8)

23 (27.5)

Median time to progression (IQR) [months]

11 (9)

16 (5)

9 (4)

Progression during FU (appearance of new WF)¹

11 (23.9)

5 (50.0)

6 (16.7)

 Cyst size ≥ 3 cm

2

0

2

 Cyst growth rate of ≥ 5 mm/2 years

9

5

4

 Thickened or enhancing cyst walls

4

1

3

 MPD-size ≥ 5 mm

1

0

1

 High-grade dysplasia on EUS-FNA

0

0

0

Surgery

5 (10.9)

2 (20.0)

3 (8.3)

 IPMN progression (rapid cyst growth)

3

2

1

 Concomitant disease

2

0

2

Surveillance status

 Active surveillance

25 (54.4)

4 (40.0)

21 (58.3)

 FU stopped (comorbidities)

2 (4.3)

1 (10.0)

1 (2.8)

 FU stopped (death)

1 (2.2)

0 (0.0)

1 (2.8)

 FU stopped (regression, disease stability)

2 (4.3)

1 (10.0)

1 (2.8)

 Patient did not wish to continue FU

9 (19.6)

2 (20.0)

7 (19.4)

 Lost to follow-up

2 (4.3)

0 (0.0)

2 (5.6)